Clinical trials: Solid Malignant Tumor
Advanced Solid Tumor
Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.
The goal of this clinical trial is to find a new radioimmunotherapy regimen for advanced malignancies with multiple metastatic after standard treatment failure/drug resistance.
- Trial name
- NCT06173219
- Testing
- Radiotherapy combined with immunotherapy
- Where
- China
- Volunteers
- 38 people
- Sponsor
- China-Japan Friendship Hospital
Oligometastatic Malignant Solid Neoplasm
Systemic Therapy With or Without Local Consolidative Therapy in Treating Patients With Oligometastatic Solid Tumor
This phase II trial studies how well systemic therapy with or without local consolidative therapy work in treating patients with solid tumor that has spread to 1 site of other places in the body.
- Trial name
- NCT03599765
- Testing
- Best Practice, Local Consolidation Therapy
- Where
- 12 sites in United States
- Volunteers
- 380 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced or Recurrent Solid Tumors, FGFR Gene Alterations
NCCH2006/MK010 Trial (FORTUNE Trial)
This is a single-arm, open-label, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of E7090 in patients with advanced or recurrent solid tumors harboring FGFR genetic alterations (including…
- Trial name
- NCT04962867
- Testing
- E7090
- Where
- 7 sites in Japan
- Volunteers
- 75 people
- Sponsor
- National Cancer Center, Japan
Tumor, Cancer
Dose Escalation of Hypofractionated Radiation Therapy in Patients With Metastatic Cancer
Patients with metastatic cancer are generally treated with chemotherapy, which has improved median survival compared to best supportive care.
- Conditions
- Tumor, Cancer, Melanoma, Sarcoma
- Trial name
- NCT01215500
- Testing
- Hypofractionated RT
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Chicago
Advanced Solid Tumors
A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor activity of AP505 injection in patients with advanced solid tumors.
- Trial name
- NCT06723964
- Testing
- AP505
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- AP Biosciences Inc.
Breast Cancer, Colorectal Cancer
Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer
- Trial name
- NCT00369109
- Testing
- biologic sample preservation procedure, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
This phase III trial compares BBT-CI to HEAL for the reduction of insomnia in patients with stage I-IV cancer who are receiving cancer treatment. Cancer treatment can cause side effects such as sleep problems.
- Trial name
- BBT-II (NCT04829539)
- Testing
- Behavioral Intervention, Electronic Health Record Review, Quality-of-Life Assessment
- Where
- 153 sites in United States
- Volunteers
- 400 people
- Sponsor
- University of Rochester NCORP Research Base
Advanced Solid Tumor
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
The global objective of this Basket of Basket study is to evaluate the antitumor activity of each matched therapies that will be evaluated through the study in small molecularly selected populations.
- Trial name
- BoB (NCT03767075)
- Testing
- Atezolizumab, Futibatinib, Amivantamab
- Where
- 8 sites in France, Germany and 5 more
- Volunteers
- 1,000 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Advanced / Metastatic Solid Tumor
A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A administered orally as a monotherapy or in combination with an immune checkpoint…
- Trial name
- NCT06063681
- Testing
- SR-8541A, Immune checkpoint inhibitor (ICI)
- Where
- 3 sites in Australia
- Volunteers
- 25 people
- Sponsor
- Stingray Therapeutics
Solid Tumor
A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin
AB-106-C111 is China-only study, for investigating the drug interaction between AB-106 and P-gp substrate (Digoxin). （n=16）
- Trial name
- NCT05357911
- Testing
- AB-106, digoxin
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nuvation Bio Inc.
Lymphoma, Small Intestine Cancer
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced solid…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00025129
- Testing
- laromustine
- Where
- 3 sites in United States
- Sponsor
- Vion Pharmaceuticals
Urachal Cancer, Parathyroid Carcinoma
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.
- Conditions
- Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma
- Trial name
- ANTARES (NCT06638931)
- Testing
- Nivolumab
- Where
- 5 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Solid Tumor
GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies
The primary objective of the study is to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and pharmacokinetics (PK) of acasunlimab (also known as GEN1046) administered as monotherapy or in combination with…
- Trial name
- NCT04937153
- Testing
- Acasunlimab, Pembrolizumab
- Where
- 2 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Genmab
Ovarian Cancer
Ultrasound RF Data for Discriminating Between Benign and Malignant Ovarian Masses
Ultrasound imaging provides useful information for the characterization of ovarian masses as benign or malignant. The most accurate mathematical model to categorize ovarian masses is the IOTA ADNEX model.This model estimates the…
- Trial name
- RFDATA (NCT06473766)
- Testing
- RF data extraction
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Advanced Solid Tumor
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors.
- Trial name
- NCT05879822
- Testing
- INCB099280
- Where
- 54 sites in Brazil, China and 7 more
- Volunteers
- 73 people
- Sponsor
- Incyte Corporation
Advanced Solid Tumor
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Objectives: To characterize safety, tolerability, MTD and OBD of intratumoral injection of SGN1 in patients with advanced solid tumors, and to preliminarily investigate the efficacy and safety of SGN1 in specific tumor subtypes.
- Trial name
- NCT05103345
- Testing
- SGN1
- Where
- 4 sites in China, Taiwan
- Volunteers
- 70 people
- Sponsor
- Guangzhou Sinogen Pharmaceutical Co., Ltd
Solid Tumor
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
This is a 3+3 dose escalation phase I study which aims to evaluate the safety and tolerability of low dose radiotherapy (LDRT) plus concurrent partial Stereotactic Ablative Radiotherapy (SBRT) and Tislelizumab in Patients with…
- Trial name
- NCT06349837
- Testing
- Tislelizumab, Low Dose Radiotherapy, Stereotactic Ablative Radiotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sichuan University
Rare Malignant Neoplasm, Advanced Solid Tumors
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
The goal of this Phase I/II observational and interventional platform study is to evaluate the safety and efficacy of multiple types of innovative anti-tumor drugs and new technologies in patients with rare solid tumors.
- Conditions
- Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors
- Trial name
- NCT07307053
- Testing
- BL-B01D1, VSV injection, CVL006
- Volunteers
- 600 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Constipation, Impaction, and Bowel Obstruction, Unspecified Adult Solid Tumor, Protocol Specific
S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and Bowel Obstruction
This partially randomized clinical trial studies surgery or non-surgical management in treating patients with intra-abdominal cancer and bowel obstruction.
- Trial name
- NCT02270450
- Testing
- therapeutic conventional surgery, gastrointestinal complications management/prevention, quality-of-life assessment
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 221 people
- Sponsor
- SWOG Cancer Research Network
Advanced Solid Tumor, Advanced Breast Cancer
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors
This trial is a first-in-human, open label, multi-center, dose escalation phase 1a study followed by a disease-specific dose expansion phase 1b study to evaluate the safety, efficacy, and pharmacokinetics (PK) of IMM2902, a…
- Conditions
- Advanced Solid Tumor, Advanced Breast Cancer, Advanced Gastric Cancer
- Trial name
- NCT05076591
- Testing
- IMM2902
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.